Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helicase eIF4A with zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic triple-negative breast cancer (TNBC) mouse models. Zotatifin not only suppresses tumor cell proliferation but also directly repolarizes macrophages toward an M1-like phenotype and inhibits neutrophil infiltration, which sensitizes tumors to immune checkpoint blockade. Mechanistic studies revealed that zotatifin reprograms the tumor translational landscape, inhibits the translation of Sox4 and Fgfr1, and induces an interferon (IFN) response uniformly across models. The induction of an IFN response is partially due to the inhibition of Sox4 translation by zotatifin. A similar induction of IFN-stimulated genes was observed in breast cancer patient biopsies following zotatifin treatment. Surprisingly, zotatifin significantly synergizes with carboplatin to trigger DNA damage and an even heightened IFN response, resulting in T cell-dependent tumor suppression. These studies identified a vulnerability of eIF4A in TNBC, potential pharmacodynamic biomarkers for zotatifin, and provide a rationale for new combination regimens consisting of zotatifin and chemotherapy or immunotherapy as treatments for TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“eIF4A inhibitors, which target both isoforms, suppress translation of key oncogenes and have demonstrated antitumor activity in a variety of cancers (15, 17, 19–22).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, eIF4A1 is essential for embryonic development in mice (18) and in various cancer cell lines (19), whereas eIF4A2 is not.”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“For proteomics data, differential analysis was performed using the moderated t test, as implemented in limma (64).”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · cited 8×
“In summary, strategies to augment ICB and chemotherapy are needed for TNBC treatment.”
InfluentialMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528 · cited 1×
“High infiltration of immunosuppressive macrophages and neutrophils is associated with a poor response to ICB (28, 36–39).”
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454 · cited 2×
“…effect is not due to a nonspecific stress response, as zotatifin did not increase the phosphorylation of eIF2 α , an integrated stress response marker, nor M1-like tumor-inhibitory phenotype (35), zotatifin treatment increased the percentage of iNOS + cells as compared with the vehicle (Figure 2G).”
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Cited by
Cencic, R., Im, Y. K., Naineni, S. K., Moustafa-Kamal, M., Jovanovic, P., Sabourin, V., Annis, M. G., Robert, F., Schmeing, T. M., Koromilas, A. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318093121 · Cited by 32
Pastena, P., Perera, H., Martinino, A., Kartsonis, W., & Giovinazzo, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052559 · Cited by 27
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Lizardo, M. M., Hughes, C. S., Huang, Y. Z., Shyp, T., Delaidelli, A., Zhang, H., Shaool, S. S., Renner, A. F., Burwag, F., Sayles, L. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1317 · Cited by 20
Yuan, X., Hao, X., Chan, H. L., Zhao, N., Pedroza, D. A., Liu, F., Le, K., Smith, A. J., Calderon, S. J., Lieu, N., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.182621 · Cited by 18
Self-citationBoyer, J. A., Rosen, E. Y., Sharma, M., Dorso, M. A., Mai, N., Amor, C., Reiter, J., Kannan, R., Gadal, S., Xu, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2424286122 · Cited by 20
eIF4F-mediated dysregulation of mRNA translation in cancer
Amiri, M., Mahmood, N., Tahmasebi, S., & Sonenberg, N. (2025) · RNA · doi:10.1261/rna.080340.124 · Cited by 18
Kang, N., Zou, B., Yu, Y., Cai, T., Luo, Z., Guo, Y., Wu, Y., Shen, X., Li, H., Fang, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202506925 · Cited by 16
RNA-binding proteins DND1 and NANOS3 cooperatively suppress the entry of germ cell lineage
Wang, Z., Yu, H., Gu, Z., Shi, X., Ma, J., Shao, Q., Yao, Y., Yao, S., Xu, Y., Gu, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57490-6 · Cited by 14
Manara, P., Newsam, A. D., Saralamma, V. V. G., Cunningham, T. A., Lazenby, D., Ho, J. J. D., Russo, M. V., Alaoui, A. Y., Chahar, D., Martinez, A. B., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3420 · Cited by 13
He, L., Zhang, X., Shi, F., Zhang, H., Chen, Y., Sun, K., Yang, H., Shi, J., Lin, Z., Lu, Q., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101731 · Cited by 14
“25 We found that targeting eIF4G1 was more effective in suppressing PDAC compared with eIF4Ei or eIF4Ai therapy; although this may be due to the difference in the inhibitory effectiveness, consideration of eIF4G targeting should be added in the strategy of disrupting eIF4F complex.”
Oblinger, J. L., Wang, J., Wetherell, G. D., Agarwal, G., Wilson, T. A., Benson, N., Fenger, J. M., Fuchs, J. R., Kinghorn, A. D., & Chang, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-69171-3 · Cited by 9
Chaudhury, A., Kongchan, N., Massey, S., Sharma, R., Pal, R., Zhao, N., Tsoi, P. S., Zhu, Y., Olokpa, E., Mao, S., et al. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag123 · Cited by 6
Self-citationNanomaterials for delivery of drugs and genes to disrupt notch signaling pathway in breast cancer
Gummadi, R., Nori, L. P., Pindiprolu, S. K. S. S., Dasari, N., Ahmad, Z., & Km, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04082-2 · Cited by 4
Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma
Mi, W., Cigliano, A., Galleri, G., Gigante, I., Steinmann, S. M., Cibali, E., Serra, M., Pes, G. M., Schlösser, D., Pizzuto, E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101416 · Cited by 3
van Genugten, J. H. L. T., Faulkner, D., Hahne, J. C., Poile, C., Wessels, L. F. A., Fennell, D. A., & Baas, P. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108769 · Cited by 3
Immune Modulatory Profile of the Pateamines PatA and Des-Methyl Des-Amino PatA
Schiffmann, S., Henke, M., Brünner, S., Bennett, A., Yagubi, Y., Magari, F., Parnham, M. J., & Grünweller, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111430 · Cited by 2
Shi, J.-Y., Wen, R., Chen, J., Feng, Y.-Q., Zhang, Y., Hou, S.-J., Xi, Y., Wang, J.-F., & Zhang, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-71059-1 · Cited by 3
Wang, W., Yang, H. J., Miao, Y., & Yao, L. (2025) · American Journal of Cancer Research · doi:10.62347/gcge6470 · Cited by 1
Li, X., Zhan, H., Zhang, X., Li, J., Li, X., Lu, X., Miao, C., Zhou, C., & Zhang, Z. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1566205 · Cited by 1
Valdés-Torres, P., Campos, D., Galán-Jurado, P. E., Zegarra, D., Lorenzo, I. T., González-Castillo, F., Blanquer, M., Mewa, J. C., Rivas, C., & González, J. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1752166 · Cited by 2
Potential therapeutic targets of eukaryotic translation initiation factors in tumor therapy
Zhang, Y., Liu, T., Li, P., Xing, Z., Mi, L., He, T., Wei, T., & Wu, W. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117638 · Cited by 1
Targeting eIF4A-dependent translation in genetically complex sarcoma
Kim, Y.-M., Mohan, P., Sehrawat, U., Seffar, E., De Queiroz, R. M., Chadalavada, K., Persaud, N., Okada, T., Kulkarni, A., Lin, J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.192936
Targeting the translation initiation complex in therapy-resistant and metastatic melanomaPreprint
Feng, Y., Diaz-Olea, X., Ke, X., Radaeva, M., Amiri, M., Joo, H., Jafari, M., Kim, H., Deshpande, A. J., Olson, S. H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.20.624566
Structural Features and Signaling Mechanisms of Receptor Tyrosine Kinases in Cancer
Kumar, R., Yadav, M., Tanwar, P., Pal, S., & Sabarwal, A. (2025) · Springer eBooks · doi:10.1007/978-981-96-7336-0_1
In Silico Perspectives on Triple Negative Breast Cancer: Challenges and Progress
Taqi, M., Yousuf, A., Shaikh, S., Soomro, F., Qureshi, A. S., & Rengasamy, K. R. R. (2025) · BioMed Target Journal · doi:10.59786/bmtj.311
Peptide antibody tools to dissect specific functions of eIF4A paralogs in cancer
Srivastava, S., Osikoya, A., Terrero, D., & Raman, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-04155-x
Smith, A. J., Schrank, Z., Guan, N., Pedroza, D. A., Calderon, S. J., Yuan, X., Zhao, N., Gabriel, Z., Gao, Y., Rivas, C. H., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-26-0278
Self-citationRamírez-Salazar, E. G., Slipicevic, A., Juraleviciute, M., Li, L., Harland, M., O'Shea, S. J., Field, S., Newton-Bishop, J., & Herlyn, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062617
Werner, T., Thiery, J., Budau, K.-L., Topitsch, A., Cosenza‐Contreras, M., Pinter, N., Hause, F., Rühlmann, J., Gentile, G., Heyer, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70817-1
Banjare, N., Singh, M., Kuiry, A., & Gupta, P. N. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115798
Rios-Fuller, T. J., Saavedra, H. I., & Schneider, R. J. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100018
Manara, P., & Schatz, J. H. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01848-6
DNA and RNA helicase inhibitors as therapeutics
Castro, J. (2026) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2026.10.022
Lin, H.-Y., Wang, S.-M., & Chu, P. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00853-6
Metadata
- Authors
- Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., Smith, A. J., Hamor, C., Safari, K., Savage, S., Zhang, B., Zhou, J., Solis, L. M., Hilsenbeck, S. G., Fan, C., Perou, C. M., & Rosen, J. M.
- Affiliations
- Baylor College of Medicine (US)
- Texas A&M Health Science Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Rosen, Jeffrey M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2023-12-15
- Volume
- 133
- Issue
- 24
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10721161
- OpenAlex
- W4387909059
- Cited by
- 30
- References
- 68
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- NIH (CA16303-46)
- CPRIT (RP220468)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- eIF4A, triple-negative breast cancer, mRNA translation inhibition, interferon response, tumor immune microenvironment, macrophage polarization, neutrophil infiltration, immune checkpoint blockade, FGFR1, carboplatin, combination therapy, pharmacodynamic biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Interferons, Cell Line, Tumor, Cell Proliferation, Mice, Tumor Microenvironment, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.